RPS29P8: A Promising Drug Target / Biomarker (G100132376)

Target Name: RPS29P8

NCBI ID: G100132376

RPS29P8

Other Name(s): ribosomal protein S29 pseudogene 8 | Ribosomal protein S29 pseudogene 8 | RPS29_5_283

RPS29P8: A Promising Drug Target / Biomarker

RPS29P8 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and muscle. Its full name is Rho-associated protein 29P8, and it is also known as PA280. RPS29P8 is a 28 kDa protein that is involved in a variety of cellular processes, including cell signaling, DNA replication, and chromatin remodeling.

The RPS29P8 gene was first identified in 2007, and since then, research has continued to explore its functions in various biological processes. One of the most significant findings related to RPS29P8 is its role as a drug target. In this article, we will explore the potential of RPS29P8 as a drug target and discuss its potential as a biomarker for various diseases.

Drug Target Potential

RPS29P8 has been identified as a potential drug target due to its involvement in various cellular processes that are associated with the development and progression of various diseases. One of the most significant findings related to RPS29P8 is its role in cancer development. RPS29P8 has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development and progression of cancer.

Studies have shown that RPS29P8 is involved in the regulation of the G1/S transition, which is a critical step in the cell cycle. During the G1 phase, cells prepare for cell division by producing duplicate copies of their chromosomes. During the S phase, the chromosomes are replicated and the cell divides. RPS29P8 has been shown to be involved in the regulation of the G1/S transition by activating the kinase S/TK2.

Another study showed that RPS29P8 was involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. RPS29P8 has been shown to be involved in the regulation of angiogenesis by activating the transcription factor, PDGFR-尾.

In addition to its role in cancer development, RPS29P8 has also been shown to be involved in the regulation of other cellular processes that are associated with the development and progression of diseases. For example, RPS29P8 has been shown to be involved in the regulation of neurodegeneration, which is the process by which the brain and other nervous system cells die or are damaged.

Biomarker Potential

RPS29P8 has also been identified as a potential biomarker for various diseases due to its involvement in various cellular processes that are associated with the development and progression of these diseases. One of the most significant findings related to RPS29P8 is its role in the regulation of inflammation. RPS29P8 has been shown to be involved in the regulation of inflammation by activating the transcription factor, NF-kappa-B.

Studies have shown that RPS29P8 is involved in the regulation of inflammation by activating the NF-kappa-B signaling pathway. NF-kappa-B is a transcription factor that is involved in the regulation of inflammation, immune response, and cellular signaling. RPS29P8 has been shown to be involved in the regulation of NF-kappa-B signaling by activating the transcription factor, nuclear factor of activated T cells (NFAT), which is a transcription factor that is involved in the regulation of cellular processes that are associated with inflammation.

Another study showed that RPS29P8 was involved in the regulation of cellular stress, which is the process by which cells respond to and recover from

Protein Name: Ribosomal Protein S29 Pseudogene 8

The "RPS29P8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS29P8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets